SEC Form 4 · accession 0001875714-26-000007
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Pieper
Officer — See Remarks
Period of report
Jul 6, 2026
Accepted (ET)
Jul 7, 2026 · 5:11 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 6, 2026 | S | 17,400 | $8.50 | D | 1,393,653 | D | |
| Common StockF3 | Jul 7, 2026 | S | 27,600 | $8.5245 | D | 1,366,053 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
- F2Includes 2,113 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Remarks
Chief Financial Officer